Key facts
- Precision Cell Systems’s last known valuation is $19.0M (Feb 2025).
- It has raised $4.0M; the latest was Early Stage VC ($4.0M) in Feb 2025.
- Notable investors include BroadOak Capital Partners.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Precision Cell Systems
- ·The full record, as it builds
Funding rounds
No funding rounds for Precision Cell Systems are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Precision Cell Systems
Developer of automated cell processing systems designed for biomedical research and therapeutic development. The company provides a comprehensive approach to sample preparation and analysis, enabling clients to create an integrated suite of automated cellular solutions.
- Sector
- Healthcare
- HQ
- Livermore, CA, United States
- Website
- precisioncellsystems.com/
- Ownership
- Privately Held (backing)
Precision Cell Systems doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Precision Cell Systems shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Precision Cell Systems in its N-PORT filings yet. We sweep new filings monthly.